Literature DB >> 34396420

Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report.

Karim Souaid, Bénédicte Oulès, Pierre Sohier, Lydia Deschamps, Sélim Aractingi1, Nicolas Dupin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34396420      PMCID： PMC9455332          DOI： 10.2340/00015555-3888

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  6 in total

1.  Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic.

Authors:  Thomas Hubiche; Nathalie Cardot-Leccia; Florence Le Duff; Barbara Seitz-Polski; Pascal Giordana; Christine Chiaverini; Valérie Giordanengo; Géraldine Gonfrier; Vincent Raimondi; Olivier Bausset; Zoubir Adjtoutah; Margaux Garnier; Fanny Burel-Vandenbos; Bérengère Dadone-Montaudié; Véréna Fassbender; Aurélia Palladini; Johan Courjon; Véronique Mondain; Julie Contenti; Jean Dellamonica; Georges Leftheriotis; Thierry Passeron
Journal:  JAMA Dermatol       Date:  2021-02-01       Impact factor: 10.282

2.  Histopathologic Features of Chilblainlike Lesions Developing in the Setting of the Coronavirus Disease 2019 (COVID-19) Pandemic.

Authors:  Pierre Sohier; Stéphanie Matar; Jean-François Meritet; Sara Laurent-Roussel; Nicolas Dupin; Selim Aractingi
Journal:  Arch Pathol Lab Med       Date:  2021-02-01       Impact factor: 5.534

3.  Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic.

Authors:  Roland Aschoff; Nick Zimmermann; Stefan Beissert; Claudia Günther
Journal:  Dermatopathology (Basel)       Date:  2020-12-04

4.  Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.

Authors:  Devon E McMahon; Erin Amerson; Misha Rosenbach; Jules B Lipoff; Danna Moustafa; Anisha Tyagi; Seemal R Desai; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Kimberly G Blumenthal; Lindy P Fox; Esther E Freeman
Journal:  J Am Acad Dermatol       Date:  2021-04-07       Impact factor: 11.527

5.  Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.

Authors:  L Le Cleach; L Dousset; H Assier; S Fourati; S Barbarot; C Boulard; C Bourseau Quetier; L Cambon; C Cazanave; A Colin; E Kostrzewa; C Lesort; A Levy Roy; F Lombart; J Marco-Bonnet; J-B Monfort; M Samimi; M Tardieu; P Wolkenstein; E Sbidian; M Beylot-Barry
Journal:  Br J Dermatol       Date:  2020-08-09       Impact factor: 11.113

6.  Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.

Authors:  S Matar; B Oulès; P Sohier; O Chosidow; M Beylot-Barry; N Dupin; S Aractingi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-20       Impact factor: 9.228
  6 in total
  2 in total

Review 1.  SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.

Authors:  Gianluca Avallone; Pietro Quaglino; Francesco Cavallo; Gabriele Roccuzzo; Simone Ribero; Iris Zalaudek; Claudio Conforti
Journal:  Int J Dermatol       Date:  2022-02-09       Impact factor: 3.204

Review 2.  "COVID toes": A true viral phenomenon or a diagnosis without a leg to stand on?

Authors:  Jia C Gao; Alisen Huang; Ankuri Desai; Bijan Safai; Shoshana Marmon
Journal:  JAAD Int       Date:  2022-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.